Reference : L'adiponectine: une nouvelle adipocytokine.
Scientific journals : Article
Human health sciences : Endocrinology, metabolism & nutrition
http://hdl.handle.net/2268/12505
L'adiponectine: une nouvelle adipocytokine.
French
[en] Adiponectin: a new adipocytokine
Lebas, Eglantine mailto [Centre Hospitalier Universitaire de Liège - CHU > > Dermatologie >]
Paquot, Nicolas mailto [Centre Hospitalier Universitaire de Liège - CHU > > Diabétologie,nutrition, maladies métaboliques >]
Scheen, André mailto [Université de Liège - ULiège > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale >]
2003
Revue Médicale de Liège
58
9
554-8
Yes (verified by ORBi)
National
0370-629X
Belgium
[en] Adiponectin ; Adipose Tissue/physiopathology ; Coronary Artery Disease/physiopathology ; Humans ; Insulin Resistance/physiology ; Intercellular Signaling Peptides and Proteins ; Proteins/physiology ; Receptors, Cytoplasmic and Nuclear/metabolism ; Thiazolidinediones/metabolism ; Tumor Necrosis Factor-alpha/metabolism
[en] Adipose tissue is not simply a store of excess energy, but also secretes a variety of proteins into circulating blood that influence systemic metabolism. These include tumor necrosis factor (TNF-alpha), plasminogen activator inhibitor type 1 (PAI-1), leptin, resistine and adiponectin. These are collectively known as adipocytokines. Adiponectin (also referred to as AdipoQ, Acrp 30, apM1 or GBP28) is a novel adipose-specific protein. A recent genome study mapped a susceptibility locus for type 2 diabetes and the metabolic syndrome on chromosome 3q27, where the adiponectin gene is located. Adiponectin is a peculiar adipocytokine because in contrast to the markedly increased levels of many others, as leptin or TNF-alpha, its level is reduced in obesity and type 2 diabetes. The administration of thiazolidinediones, which are synthetic PPARs-gamma ligands, significantly increases the plasma adiponectin concentrations, an effect that could improve insulin sensitivity. Thus, the administration of adiponectin may provide a novel treatment modality for insulin resistance and type 2 diabetes.
Researchers ; Professionals ; Students
http://hdl.handle.net/2268/12505
http://www.rmlg.ulg.ac.be

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Open access
200309_09.pdfNo commentaryPublisher postprint446.94 kBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.